Truist has adjusted its price target for Intuitive Surgical (ISRG, Financial), lowering it to $590 from a previous $605 while maintaining a Buy rating on the stock. This revision follows the company's recent quarterly results. Despite acknowledging challenges, the firm noted the earnings call and outlook exceeded concerns sparked by broader economic uncertainties.
Truist remains optimistic about Intuitive Surgical's long-term prospects. The firm suggests that investors may consider capitalizing on economic downturns by revisiting or increasing their holdings in ISRG. This marks an ongoing belief in the company’s potential for sustained growth in the face of macroeconomic challenges.
